Androgen Receptor Gene Variants and Breast Cancer Risk
Author Information
Author(s): Kadouri L, Easton D F, Edwards S, Hubert A, Kote-Jarai Z, Glaser B, Durocher F, Abeliovich D, Peretz T, Eeles R A
Primary Institution: Sharett Institute of Oncology, Hebrew University-Hadassah Medical Center, Jerusalem, Israel
Hypothesis
Do CAG and GGC repeat polymorphisms in the androgen receptor gene affect breast cancer susceptibility in BRCA1/2 carriers and non-carriers?
Conclusion
The study found no significant association between androgen receptor repeat lengths and breast cancer risk in BRCA1/2 carriers or the general population.
Supporting Evidence
- The study genotyped 188 BRCA1/2 carriers and controls for AR CAG and GGC repeats.
- No association was found between the repeats and breast cancer risk in either BRCA1/2 carriers or the general population.
- The estimated relative risk of breast cancer in carriers associated with ≥28 CAG repeats was 1.08.
Takeaway
The length of certain gene repeats in the androgen receptor doesn't seem to change the risk of breast cancer for people with BRCA1 or BRCA2 mutations.
Methodology
Genotyping of BRCA1/2 carriers and controls for AR CAG and GGC repeats, followed by risk analyses using a variant of the log-rank test.
Limitations
The study did not find significant associations, which may suggest limitations in the genetic factors considered.
Participant Demographics
188 BRCA1/2 carriers (122 affected, 66 unaffected), 166 breast cancer cases without BRCA1/2 mutations, and 156 Ashkenazi controls aged over 56.
Statistical Information
Confidence Interval
95%CI 0.97–1.17 for CAG repeats and 95%CI 0.80–1.15 for GGC repeats.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website